Last reviewed · How we verify
Ftivazid (FTIVAZIDE)
Ftivazid (generic name: FTIVAZIDE) is a ftivazide drug. It is currently in Phase 2 development for Tuberculosis.
Ftivazid works by inhibiting the activity of myeloperoxidase, an enzyme that contributes to the development of tuberculosis.
Ftivazid (FTIVAZIDE) is a small molecule drug developed to target myeloperoxidase, a key enzyme involved in the pathogenesis of tuberculosis. It is classified as a ftivazide and has been approved for the treatment of tuberculosis. The commercial status of ftivazid is currently unknown, and it is not clear if it is patented or available as a generic medication. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also not available. As a result, key safety considerations and potential side effects are not well established.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FTIVAZIDE |
|---|---|
| Drug class | ftivazide |
| Target | Myeloperoxidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Think of myeloperoxidase like a fire starter in your body. When it's working properly, it helps fight off infections. But in the case of tuberculosis, this enzyme can actually make the infection worse. Ftivazid helps by putting the brakes on myeloperoxidase, which can help reduce the severity of the infection.
Approved indications
- Tuberculosis
Common side effects
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2,PHASE3)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ftivazid CI brief — competitive landscape report
- Ftivazid updates RSS · CI watch RSS
Frequently asked questions about Ftivazid
What is Ftivazid?
How does Ftivazid work?
What is Ftivazid used for?
What is the generic name of Ftivazid?
What drug class is Ftivazid in?
What development phase is Ftivazid in?
What does Ftivazid target?
Related
- Drug class: All ftivazide drugs
- Target: All drugs targeting Myeloperoxidase
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Tuberculosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing